- Home
- FAMI vs MDCX Comparison
FAMI vs MDCX Comparison
Compare FAMI & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FAMI | MDCX |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | China | United States |
| Employees | N/A | 16 |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7M | 16.6M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | FAMI | MDCX |
|---|---|---|
| Price | $1.34 | $0.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 21.0K | ★ 1.7M |
| Earning Date | 08-04-2025 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $0.25 |
| 52 Week High | $2.12 | $3.69 |
Technical Indicators
Market Signals| Indicator | FAMI | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 58.76 |
| Support Level | $1.35 | $0.38 |
| Resistance Level | $1.49 | $0.52 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 59.09 | 97.89 |
Price Performance
Historical ComparisonAbout FAMI Farmmi Inc.
Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe and the Middle East under the Forasen and Farmmi brands.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.